- Home
- ENVB vs PRFX Comparison
ENVB vs PRFX Comparison
Compare ENVB & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENVB | PRFX |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 1.6M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ENVB | PRFX |
|---|---|---|
| Price | $1.95 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.3K | ★ 329.1K |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,914,675.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.58 |
| 52 Week High | $13.25 | $3.71 |
Technical Indicators
Market Signals| Indicator | ENVB | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 57.57 |
| Support Level | $1.81 | $1.28 |
| Resistance Level | $2.06 | $2.91 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 44.44 | 80.62 |
Price Performance
Historical ComparisonAbout ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.